Distinguished in Squamous Cell Lung Carcinoma

Dr. Patrick M. Forde

Hematology Oncology | Oncology
401 North Broadway, Weinberg Bdg., 
Baltimore, MD 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Distinguished in Squamous Cell Lung Carcinoma
401 North Broadway, Weinberg Bdg., 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Small Cell Lung Cancer (SCLC). Dr. Forde is currently accepting new patients.

His clinical research consists of co-authoring 180 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Irish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

401 North Broadway, Weinberg Bdg., Baltimore, MD 21231

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: July 18, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Enrollment Status: Completed
Publish Date: June 13, 2025
Intervention Type: Biological, Drug
Study Drugs: LGK974, PDR001
Study Phase: Phase 1
Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Preoperative Immune Checkpoint Inhibitor Therapy for Patients With Primary Untreated or Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (RM-SCCHN)
Enrollment Status: Completed
Publish Date: November 21, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Biological, Other
Study Drugs: Anetumab Ravtansine, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 06, 2023
Intervention Type: Drug
Study Drugs: MBG453, PDR001, Decitabine
Study Phase: Phase 1/Phase 2
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Enrollment Status: Terminated
Publish Date: August 28, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 15 Less Clinical Trials

180 Total Publications

Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis.
Macrophage CCL18 Promotes Lung Inflammation in Checkpoint Inhibitor Pneumonitis.
Journal: American journal of respiratory cell and molecular biology
Published: October 10, 2025
Similar Doctors
Elite in Squamous Cell Lung Carcinoma
Dr. Benjamin P. Levy
Hematology Oncology | Hematology | Oncology
Elite in Squamous Cell Lung Carcinoma
Dr. Benjamin P. Levy
Hematology Oncology | Hematology | Oncology

Johns Hopkins University

5755 Cedar Ln, 
Columbia, MD 
 (16.6 miles away)
410-740-7544
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Levy is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Levy is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Christine L. Hann
Hematology Oncology | Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Christine L. Hann
Hematology Oncology | Oncology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (0.1 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christine Hann is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma. Dr. Hann is currently accepting new patients.

Distinguished in Squamous Cell Lung Carcinoma
Dr. Josephine L. Feliciano
Hematology Oncology | Hematology | Oncology
Distinguished in Squamous Cell Lung Carcinoma
Dr. Josephine L. Feliciano
Hematology Oncology | Hematology | Oncology

Johns Hopkins University

4940 Eastern Ave, 
Baltimore, MD 
 (2.6 miles away)
410-550-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Josephine Feliciano is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feliciano is rated as an Elite provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Feliciano is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Forde's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile